RecruitingNCT07145918
This study is comparing Emraclidine with placebo for people with Schizophrenia. Participants receive Emraclidine or placebo and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- AbbVie
- Condition
- Schizophrenia
RecruitingNCT05102929
This study is looking at care and outcomes for people with Schizophrenia. Some participants may receive active, then sham Intermittent Theta Burst Stimulation (iTBS) over DLPFC instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 18 Years to 40 Years
- Countries
- United States
- Sponsor
- Fabio Ferrarelli
- Condition
- Schizophrenia
RecruitingNCT05656469
This study is looking at whether Personalised medication advice based on pharmacogenetic testing can help people with anxiety or psychosis. Participants receive a study treatment and complete follow-up visits and assessments.
AnxietyOtherFrom 16 Years to 65 Years
- Countries
- Germany, Netherlands, Romania, Serbia, Spain, United Kingdom, United States
- Sponsor
- Maastricht University Medical Center
- Condition
- Anxiety
RecruitingNCT05185128
This study is looking at whether PEERS social skills intervention can help people with Autism Spectrum Disorder, Psychosis, or Social Communication. Participants take part in PEERS social skills intervention and complete follow-up assessments.
SchizophreniaOtherFrom 12 Years to 18 Years
- Countries
- United States
- Sponsor
- Loma Linda University
- Condition
- Schizophrenia
RecruitingNCT07177261
This study is looking at care and outcomes for people with Schizophrenia Disorder. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- University of California, Los Angeles
- Condition
- Schizophrenia
Active Not RecruitingNCT04143126
This study is looking at whether Cognitive Enhancement Therapy can help people with Schizophrenia. Participants take part in Cognitive Enhancement Therapy and complete follow-up assessments.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- University of Pittsburgh
- Condition
- Schizophrenia
Enrolling By InvitationNCT01088386
This observational study is following people with Schizophrenia to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- Eli Lilly and Company
- Condition
- Schizophrenia
RecruitingNCT07184619
This study is comparing Evenamide 15 mg bid with placebo for people with Treatment-resistant Schizophrenia. Participants receive Evenamide 15 mg bid or placebo and complete study visits and assessments.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- Newron Pharmaceuticals SPA
- Condition
- Schizophrenia
RecruitingNCT03995121
This observational study is following people with Schizophrenia and Other psychosis, Cannabis Use Disorder, or Healthy to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 18 Years to 85 Years
- Countries
- United States
- Sponsor
- Yale University
- Condition
- Schizophrenia
Not Yet RecruitingNCT07342465
This study is comparing GENUS with Sham Stimulation for people with Schizophrenia Spectrum Disorders. Participants receive GENUS or Sham Stimulation and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Massachusetts Institute of Technology
- Condition
- Schizophrenia
Active Not RecruitingNCT04338152
This study is looking at whether problem-solving support can help people with psychosis, Prodromal Symptoms, Prodromal Schizophrenia, or Family. Participants take part in the therapy or support program and complete follow-up questionnaires or assessments.
SchizophreniaOtherFrom 13 Years to 25 Years
- Countries
- Canada, United States
- Sponsor
- University of California, Los Angeles
- Condition
- Schizophrenia
RecruitingNCT05208190
This observational study is following people with Schizophrenia or schizoaffective disorder to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- New York State Psychiatric Institute
- Condition
- Schizophrenia
RecruitingNCT07098169
This study is comparing iTEST with Active Control for people with Schizophrenia Disorders, schizoaffective disorder, or psychosis. Participants receive iTEST or Active Control and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- University of California, San Diego
- Condition
- Schizophrenia
RecruitingNCT07363577
This study is comparing LB-102 (50 mg tablet) with placebo for people with Schizophrenia. Participants receive LB-102 (50 mg tablet) or placebo and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- LB Pharmaceuticals Inc.
- Condition
- Schizophrenia
RecruitingNCT07344948
This observational study is following people with Healthy Participants or Schizophrenia Diagnosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Neurosterix
- Condition
- Schizophrenia
Active Not RecruitingNCT03442101
This observational study is following people with Psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 17 Years to 35 Years
- Countries
- United States
- Sponsor
- University of Alabama at Birmingham
- Condition
- Schizophrenia
RecruitingNCT06961968
This study is comparing iloperidone with placebo for people with Schizophrenia. Participants receive iloperidone or placebo and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Vanda Pharmaceuticals
- Condition
- Schizophrenia
RecruitingNCT05276050
This observational study is following people with Smoking Cessation, Nicotine Addiction, or Schizophrenia to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 22 Years to 65 Years
- Countries
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
- Condition
- Schizophrenia
RecruitingNCT06003036
This study is looking at care and outcomes for people with Schizophrenia or schizoaffective disorder. Some participants may receive iTBS, then Sham instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 18 Years to 50 Years
- Countries
- United States
- Sponsor
- Deepak K. Sarpal, M.D.
- Condition
- Schizophrenia
RecruitingNCT04411225
This study is comparing Cannabidiol oral solution with placebo for people with Early Psychosis. Participants receive Cannabidiol oral solution or placebo and complete study visits and assessments.
SchizophreniaOtherFrom 16 Years to 30 Years
- Countries
- United States
- Sponsor
- University of California, San Diego
- Condition
- Schizophrenia
RecruitingNCT06502964
This study is looking at care and outcomes for people with Schizophrenia or Cognitive Impairment. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 21 Years to 55 Years
- Countries
- United States
- Sponsor
- Alto Neuroscience
- Condition
- Schizophrenia
Not Yet RecruitingNCT06909422
This study is looking at test the inital efficacy of a brief mobile intervention targeting biased thinking for people with Schizophrenia or Clinical High Risk for Psychosis. Participants take part in Mobile Intervention for Biased Thinking and complete follow-up assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- University of Alabama at Birmingham
- Condition
- Schizophrenia
Not Yet RecruitingNCT07157293
This study is looking at whether Online Motivation Enhancing Intervention can help people with Schizophrenia Prodromal, SCHIZOPHRENIA 1, or Psychosis. Participants take part in Online Motivation Enhancing Intervention and complete follow-up assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- University of Alabama at Birmingham
- Condition
- Schizophrenia
RecruitingNCT07061288
This study is looking at evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia. Participants receive a study treatment and complete follow-up visits and assessments.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Bristol-Myers Squibb
- Condition
- Schizophrenia
RecruitingNCT07060066
This study is looking at provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia for people with Schizophrenia and Related Disorders. Some participants may receive Sham rTMS stimulation instead of the study treatment, and direct benefit is not guaranteed.
DepressionOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
- Condition
- Depression